Chen J - Search Results

1

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Among authors: chen j. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.

2

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Shaw AT, et al. Among authors: chen j. Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23. Lancet Oncol. 2017. PMID: 29074098 Free PMC article. Clinical Trial.

3

The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants.

Patel M, Chen J, McGrory S, O'Gorman M, Nepal S, Ginman K, Pithavala YK. Patel M, et al. Among authors: chen j. Invest New Drugs. 2020 Feb;38(1):131-139. doi: 10.1007/s10637-019-00872-7. Epub 2019 Nov 14. Invest New Drugs. 2020. PMID: 31728714 Clinical Trial.

4

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.

Chen J, Xu H, Pawlak S, James LP, Peltz G, Lee K, Ginman K, Bergeron M, Pithavala YK. Chen J, et al. Adv Ther. 2020 Feb;37(2):745-758. doi: 10.1007/s12325-019-01198-9. Epub 2019 Dec 20. Adv Ther. 2020. PMID: 31863284 Clinical Trial.

5

Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.

Chen J, Xu H, Pawlak S, James LP, Peltz G, Lee K, Ginman K, Bergeron M, Pithavala YK. Chen J, et al. Adv Ther. 2020 Nov;37(11):4754. doi: 10.1007/s12325-020-01480-1. Adv Ther. 2020. PMID: 32910418

6

Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.

Chen J, Houk B, Pithavala YK, Ruiz-Garcia A. Chen J, et al. CPT Pharmacometrics Syst Pharmacol. 2021 Feb;10(2):148-160. doi: 10.1002/psp4.12585. Epub 2021 Feb 1. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33449423 Free PMC article. Clinical Trial.

7

The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants.

Li J, Pithavala YK, Gong J, LaBadie RR, Mfopou JK, Chen J. Li J, et al. Among authors: chen j. Clin Pharmacokinet. 2021 Oct;60(10):1303-1312. doi: 10.1007/s40262-021-01026-w. Epub 2021 May 3. Clin Pharmacokinet. 2021. PMID: 33937953 Free PMC article. Clinical Trial.

8

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.

Chen J, O'Gorman MT, James LP, Klamerus KJ, Mugundu G, Pithavala YK. Chen J, et al. Clin Pharmacokinet. 2021 Oct;60(10):1313-1324. doi: 10.1007/s40262-021-01015-z. Epub 2021 May 3. Clin Pharmacokinet. 2021. PMID: 33937954 Free PMC article. Clinical Trial.

9

Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.

Chen J, Ruiz-Garcia A, James LP, Peltz G, Thurm H, Clancy J, Hibma J. Chen J, et al. Clin Pharmacol Ther. 2021 Nov;110(5):1273-1281. doi: 10.1002/cpt.2228. Epub 2021 Jun 26. Clin Pharmacol Ther. 2021. PMID: 33973232 Free PMC article. Clinical Trial.

10

Response to "Lorlatinib Exposed: A Far from Optimal Dose".

Chen J, Ruiz-Garcia A, James LP, Peltz G, Thurm H, Clancy J, Hibma J. Chen J, et al. Clin Pharmacol Ther. 2022 Jun;111(6):1197-1198. doi: 10.1002/cpt.2580. Epub 2022 Mar 31. Clin Pharmacol Ther. 2022. PMID: 35358326 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127,715 results

Search Page